Puma Biotechnology, Inc. (NASDAQ:PBYI) Expected to Announce Earnings of -$0.13 Per Share

Equities research analysts expect Puma Biotechnology, Inc. (NASDAQ:PBYIGet Rating) to report earnings per share (EPS) of ($0.13) for the current quarter, Zacks Investment Research reports. Two analysts have made estimates for Puma Biotechnology’s earnings. Puma Biotechnology posted earnings of $0.40 per share during the same quarter last year, which suggests a negative year-over-year growth rate of 132.5%. The company is expected to report its next earnings report on Monday, January 1st.

According to Zacks, analysts expect that Puma Biotechnology will report full year earnings of $0.16 per share for the current financial year, with EPS estimates ranging from $0.06 to $0.25. For the next financial year, analysts anticipate that the company will report earnings of $0.63 per share, with EPS estimates ranging from $0.35 to $0.91. Zacks Investment Research’s EPS averages are a mean average based on a survey of research firms that follow Puma Biotechnology.

Puma Biotechnology (NASDAQ:PBYIGet Rating) last issued its quarterly earnings results on Thursday, March 3rd. The biopharmaceutical company reported $0.10 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.11) by $0.21. Puma Biotechnology had a negative net margin of 11.49% and a negative return on equity of 357.74%. The company had revenue of $55.40 million during the quarter, compared to analysts’ expectations of $47.17 million. During the same quarter last year, the company posted ($0.38) EPS. The firm’s revenue was up 5.3% compared to the same quarter last year.

PBYI has been the topic of several analyst reports. Zacks Investment Research upgraded Puma Biotechnology from a “strong sell” rating to a “hold” rating and set a $2.25 price objective on the stock in a research note on Monday, February 14th. StockNews.com initiated coverage on Puma Biotechnology in a research note on Thursday, March 31st. They issued a “hold” rating on the stock. One research analyst has rated the stock with a sell rating, three have given a hold rating and two have given a buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $8.45.

Large investors have recently bought and sold shares of the stock. Invesco Ltd. grew its holdings in shares of Puma Biotechnology by 18.3% during the second quarter. Invesco Ltd. now owns 12,825 shares of the biopharmaceutical company’s stock worth $118,000 after purchasing an additional 1,980 shares during the last quarter. BNP Paribas Arbitrage SA grew its holdings in shares of Puma Biotechnology by 64.4% during the fourth quarter. BNP Paribas Arbitrage SA now owns 11,354 shares of the biopharmaceutical company’s stock worth $35,000 after purchasing an additional 4,447 shares during the last quarter. Principal Financial Group Inc. grew its holdings in shares of Puma Biotechnology by 13.2% during the fourth quarter. Principal Financial Group Inc. now owns 50,445 shares of the biopharmaceutical company’s stock worth $153,000 after purchasing an additional 5,883 shares during the last quarter. Diversified Trust Co grew its holdings in shares of Puma Biotechnology by 30.8% during the fourth quarter. Diversified Trust Co now owns 25,688 shares of the biopharmaceutical company’s stock worth $78,000 after purchasing an additional 6,053 shares during the last quarter. Finally, Wells Fargo & Company MN boosted its stake in shares of Puma Biotechnology by 2.9% during the second quarter. Wells Fargo & Company MN now owns 224,470 shares of the biopharmaceutical company’s stock worth $2,062,000 after buying an additional 6,314 shares during the period. 89.99% of the stock is currently owned by hedge funds and other institutional investors.

Shares of NASDAQ PBYI traded down $0.05 during mid-day trading on Friday, hitting $2.83. The company had a trading volume of 184,197 shares, compared to its average volume of 426,443. The company has a market capitalization of $116.96 million, a PE ratio of -3.93 and a beta of 1.02. Puma Biotechnology has a 1-year low of $2.06 and a 1-year high of $11.95. The business’s 50-day simple moving average is $2.68 and its 200 day simple moving average is $3.48.

About Puma Biotechnology (Get Rating)

Puma Biotechnology, Inc, a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company's drug candidates include PB272 neratinib (oral) for the patients with early stage HER2-overexpressed/amplified breast cancer; PB272 (neratinib, oral) for the use of neratinib in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer; PB272 (neratinib, oral) for HER2 mutation-positive solid tumors.

Featured Stories

Get a free copy of the Zacks research report on Puma Biotechnology (PBYI)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Puma Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Puma Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.